<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="533">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476617</url>
  </required_header>
  <id_info>
    <org_study_id>M14-243</org_study_id>
    <nct_id>NCT02476617</nct_id>
  </id_info>
  <brief_title>Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults</brief_title>
  <official_title>An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Na誰ve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic
      HCV GT1a treatment-na誰ve and pegylated-interferon (pegIFN)/RBV treatment-experienced adults
      receiving treatment with ombitasvir/ABT-450/ritonavir and dasabuvir coadministered with RBV
      for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study to evaluate the role of ombitasvir/ABT-450/ritonavir and dasabuvir coadministered
      with RBV treatment leading to sustained virologic response 12 weeks post-dosing (SVR12) on
      the changes from baseline in IFN-stimulated gene (ISG) expression in peripheral blood
      mononucleated cells (PBMCs) in HCV GT1a-infected adult subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in interferon-stimulated gene (ISG) expression in peripheral blood mononucleated cells (PBMCs)</measure>
    <time_frame>Week 0 to Post-Treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The changes from week 0 to post-treatment week 12 in key ISG expression in PBMCs for subjects achieving SVR12 is assessed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C (HCV)</condition>
  <condition>Hepatitis C Genotype 1a</condition>
  <arm_group>
    <arm_group_label>Cohort A: Treatment-naive subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-na誰ve subjects receiving ombitasvir/ABT-450/r once daily (QD) + dasabuvir twice daily (BID) + weight based RBV BID for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Previous pegIFN/RBV experienced subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previous pegIFN/RBV experienced subjects receiving ombitasvir/ABT-450/r once daily (QD) + dasabuvir twice daily (BID) + weight based RBV BID for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir/ABT-450/ritonavir</intervention_name>
    <description>ombitasvir/ABT-450/ritonavir tablets</description>
    <arm_group_label>Cohort A: Treatment-naive subjects</arm_group_label>
    <arm_group_label>Cohort B: Previous pegIFN/RBV experienced subjects</arm_group_label>
    <other_name>ABT-267/ABT-450/ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <description>dasabuvir tablets</description>
    <arm_group_label>Cohort A: Treatment-naive subjects</arm_group_label>
    <arm_group_label>Cohort B: Previous pegIFN/RBV experienced subjects</arm_group_label>
    <other_name>ABT-333</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>ribavirin tablets</description>
    <arm_group_label>Cohort A: Treatment-naive subjects</arm_group_label>
    <arm_group_label>Cohort B: Previous pegIFN/RBV experienced subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Screening laboratory result indicating HCV GT1a infection.

          2. Chronic HCV infection.

          3. Subjects must be non-cirrhotic.

          4. Subjects must be treatment-na誰ve or have documentation that they were adherent to
             prior pegIFN/RBV combination therapy and meet the criteria of prior pegIFN/RBV
             treatment failure.

          5. Subjects must meet specific human leukocyte antigen (HLA) allele requirements.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody (HIV Ab) positive immunoassay.

          3. Clinically significant abnormalities or co-morbidities, other than HCV infection,
             that make the subject unsuitable for this study or treatment.

          4. Current enrollment in another interventional clinical study, previous enrollment in
             this study, prior or current use of any investigational or commercially available
             anti-HCV agents other than pegIFN or RBV (including previous exposure to ABT-450,
             ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks
             prior to study drug administration.

          5. History or solid organ transplant.

          6. Screening laboratory analysis that shows abnormal results.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Dumas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christal Marincic, BS</last_name>
    <phone>847-231-5657</phone>
    <email>christal.marincic@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manohara Halasiddappa, BS</last_name>
    <phone>847-935-0458</phone>
    <email>manohara.halasiddappa@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128320</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128320, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment naive</keyword>
  <keyword>Interferon free</keyword>
  <keyword>HCV</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Hepatitis C Genotype 1a</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>pegIFN/RBV experienced</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
